DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Phase 3

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: ambrisentan

First Posted Date: 2007-12-21

Last Posted Date: 2013-01-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 383

Registration Number: NCT00578786

Locations: 🇦🇷
Sanatorio Otamendi, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷
Hospital Britanico-Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷
Instituto del Corazon Denton A. Cooley, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

and more 19 locations

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Large-Cell
Leukemia, Lymphocytic, Chronic
Leukemia, Prolymphocytic
Lymphoplasmacytoid Lymphoma, CLL
Lymphoma, B-Cell
Lymphoma, Intermediate-Grade
Leukemia, B-Cell, Chronic
NHL
SLL

Interventions: Biological: veltuzumab

First Posted Date: 2007-10-19

Last Posted Date: 2021-08-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 32

Registration Number: NCT00546793

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
Lewis Cancer Center and Research Pavilion, Savannah, Georgia, United States
🇺🇸
Cancer Care at Saint Clare's/Saint Clares Hospital Oncology & Hematology Specialists, P.A., Denville, New Jersey, United States

and more 2 locations

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Phase 1

Terminated

Conditions: Purpura, Thrombocytopenic, Idiopathic
Autoimmune Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Autoimmune

Interventions: Biological: veltuzumab

First Posted Date: 2007-10-19

Last Posted Date: 2021-08-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 48

Registration Number: NCT00547066

Locations: 🇺🇸
University of Southern California- Keck School of Medicine, Los Angeles, California, United States
🇺🇸
Center of Hope for Cancer and Blood Disorders, Riverdale, Georgia, United States
🇺🇸
Georgia Cancer Specialtists, Tucker, Georgia, United States

and more 4 locations

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir DF
Drug: Zidovudine
Drug: Stavudine

First Posted Date: 2007-09-14

Last Posted Date: 2018-03-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 97

Registration Number: NCT00528957

Locations: 🇵🇦
Hospital del Nino, Panama City, Panama
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Children's Diagnostic and Treatment Center, Inc, Fort Lauderdale, Florida, United States

and more 6 locations

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: FTC/TDF
Drug: Hepatitis B Immunoglobulin (HBIg)

First Posted Date: 2007-07-26

Last Posted Date: 2014-03-14

Lead Sponsor: Gilead Sciences

Target Recruit Count: 40

Registration Number: NCT00507689

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Tenofovir DF
Drug: FTC
Drug: Placebo

First Posted Date: 2007-07-26

Last Posted Date: 2015-07-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 126

Registration Number: NCT00507507

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Phase 1

Completed

Conditions: Genital Warts

Interventions: Drug: GS-9191
Drug: GS-9191 ointment
Drug: Placebo

First Posted Date: 2007-07-12

Last Posted Date: 2009-04-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 202

Registration Number: NCT00499967

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Conditions: Cystic Fibrosis
Pseudomonas Aeruginosa Airway Infection

First Posted Date: 2007-07-11

Last Posted Date: 2011-08-02

Lead Sponsor: Gilead Sciences

Registration Number: NCT00499720

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Phase 1

Terminated

Conditions: Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Multiple Myeloma

Interventions: Drug: GS-9219

First Posted Date: 2007-07-11

Last Posted Date: 2014-02-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 32

Registration Number: NCT00499239

Locations: 🇷🇺
Federal State Institution Russian Research Center of Radiology and Surgical Technologies under the Federal Agency for High-Tech Medical Care, St. Petersburg, Russian Federation
🇷🇺
State Public Medical Institution of Novosibirsk Region: State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 17 locations

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

Completed

Conditions: Kidney Disease
Renal Impairment
HIV Infections
Fanconi Syndrome

Interventions: Procedure: Blood Draws

First Posted Date: 2007-07-11

Last Posted Date: 2014-03-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 56

Registration Number: NCT00499187

Locations: 🇺🇸
University of Indiana, Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy